The Rare Disease Company Coalition, which helps educate key policy stakeholders on the unique considerations of life science companies when developing and bringing to market therapies for small and differentiated patient populations, recently published a number of compelling statistics that highlight the fact that 'the time is now' to seize the opportunity and enable positive changes to be realized for the rare disease community.
Committed to discovering, developing, and delivering rare disease treatments for the patients they serve, the life sciences representative body has announced:
~10K
Rare diseases and growing
Yet the average duration for a rare disease diagnosis is 7-8 years, and 50% of patients must live with no accurate diagnosis.
70%
Progress in motion
70% of the nearly 3,000 therapies in phase III clinical trials are from small pharmaceutical companies.
5%
The need is critical
Only 5% of rare diseases have an FDA-approved treatment.
1:10
Rare is not that rare
One in ten people lives with a rare disease and half are children.
It is due to these unique challenges - and opportunities - that Asteri Pharma continues to build relationships with global biopharmaceutical companies to determine and deliver innovative rare disease treatments for the patients in the Australian market.
For more about the role the Rare Disease Company Coalition play in assisting research through development, approval and manufacturing of therapies for rare diseases, click here.
Comments